ArticleJMA journal2025
Association between Preoperative Exercise Tolerance, Comorbidities, and Survival Rates in Patients with Pancreatic Cancer.
Article in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite treatment advancements, pancreatic cancer continues to have the lowest 5-year survival rate and a high age-adjusted mortality. Limited physical and functional reserves often restrict therapeutic options. Although the 6-minute walk distance (6MWD) and the Charlson Comorbidity Index (CCI) are established prognostic markers, their combined prognostic utility remains unexplored. This study evaluated the prognostic value of a composite index (6MWD-CCI) in patients who underwent pancreatic resection. Methods: This retrospective study included 85 patients with pancreatic cancer who underwent resection between July 2019 and September 2022. Preoperative 6MWD (<400 m) and CCI scores were used to classify patients into three 6MWD-CCI risk groups (low, middle, and high). Physical, nutritional, and frailty parameters were also assessed. Kaplan-Meier and Cox regression analyses were performed to evaluate survival outcomes, adjusting for confounders. Results: During a median follow-up of 802 days, 27 patients (31.8%) died. Low 6MWD, high CCI, and elevated 6MWD-CCI risk levels were significantly associated with reduced survival. The composite 6MWD-CCI demonstrated strong prognostic value, outperforming individual metrics even after adjustment for confounders. Conclusions: The 6MWD-CCI is a practical and predictive tool for pancreatic cancer prognosis, integrating physical function and comorbidity burden to enhance risk stratification. Its incorporation into clinical workflows could improve preoperative planning. Validation through larger studies is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.